US98956P1021 - Common Stock
/PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE: ZBH and SIX: ZBH), a global medical technology leader, today received the CE Mark for its Persona® Revision...
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.
The company is well known for its hip and knee replacements. Full-year sales will take an unexpected hit.
ZBH stock results show that Zimmer Biomet Holdings beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
At their 52-week lows, these undervalued healthcare stocks present a favorable return supported by healthcare spending tailwinds.
The company spun out from Zimmer Biomet in 2022. Now, it's a possible takeover candidate.
With prices remaining elevated above historical norms, investors still are interested in buying inflation-resistant stocks.
ZBH stock results show that Zimmer Biomet Holdings beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.